IPP 204106

Drug Profile

IPP 204106

Alternative Names: IPP-204106; IPP204106N; Nucant programme IPP-204106; polyplexed Nucant; poyplexed IPP-204106

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CNRS
  • Developer CNRS; ImmuPharma
  • Class Antineoplastics; Eye disorder therapies; Peptides; Skin disorder therapies
  • Mechanism of Action Nucleolin inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Research Age-related macular degeneration
  • No development reported Diabetic retinopathy; Psoriasis; Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in France (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in France (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for research development in Wounds in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top